头盔无创通气与常规呼吸支持对COVID-19所致急性低氧性呼吸衰竭患者死亡率的影响:HELMET-COVID随机临床试验
这项多中心、实用、随机临床试验在沙特阿拉伯和科威特的8个中心进行,纳入320例疑似或确诊COVID-19所致急性低氧性呼吸衰竭成人患者,随机接受头盔无创通气(n=159)或常规呼吸支持(n=161,包括面罩无创通气、经鼻高流量氧疗和标准氧疗)。主要终点28天全因死亡率在头盔组为27.0%(43/159),常规组为26.1%(42/161),风险差1.0%(95%CI -8.7%至10.6%),相对风险1.04(95%CI 0.72-1.49),P=0.85。28天内气管插管率头盔组47.2%(75/159) vs 常规组50.3%(81/161),风险差-3.1%(95%CI -14.1%至7.8%),相对风险0.94(95%CI 0.75-1.17)。所有预设次要终点均无显著差异。作者认为头盔无创通气未显著降低28天死亡率,但解释受效应估计不精确限制,不能排除潜在临床重要获益或危害。
要点
- 在COVID-19所致急性低氧性呼吸衰竭成人中,头盔无创通气 vs 常规呼吸支持28天死亡率27.0% vs 26.1%,RR 1.04(95%CI 0.72-1.49),P=0.85,未达统计学显著。
- 28天气管插管率头盔组47.2%(75/159) vs 常规组50.3%(81/161),RR 0.94(95%CI 0.75-1.17),未达统计学显著。
- 气压伤发生率头盔组18.9%(30/159) vs 常规组15.5%(25/161);皮肤压力性损伤头盔组3.1%(5/159) vs 常规组6.2%(10/161)。
- 严重不良事件头盔组2例 vs 常规组1例;所有预设次要终点两组间均无显著差异。
- 作者认为结果受效应估计不精确限制,不能排除潜在临床重要获益或危害。
适用人群与场景
- 成人急性低氧性呼吸衰竭患者(n=320),病因疑似或确诊COVID-19,纳入本随机临床试验。
处置流程与药物剂量
- 头盔无创通气组(n=159)接受头盔接口无创通气。
- 常规呼吸支持组(n=161)接受面罩无创通气、经鼻高流量氧疗或标准氧疗。
研究设计与关键结果
- 多中心、实用、随机临床试验,在沙特阿拉伯和科威特的8个中心进行,2021年2月8日至2021年11月16日纳入320例成人急性低氧性呼吸衰竭(疑似或确诊COVID-19)患者,随机分为头盔无创通气组(n=159)和常规呼吸支持组(n=161);主要终点最终随访日期为2021年12月14日。
- 随机322例,320例纳入主要分析,均完成试验;中位年龄58岁,男性187例(58.4%)。
- 28天全因死亡率:头盔无创通气组43/159(27.0%) vs 常规呼吸支持组42/161(26.1%),风险差1.0%(95%CI -8.7%至10.6%),相对风险1.04(95%CI 0.72-1.49),P=0.85。
- 28天内气管插管:头盔组75/159(47.2%) vs 常规组81/161(50.3%),风险差-3.1%(95%CI -14.1%至7.8%),相对风险0.94(95%CI 0.75-1.17)。
- 气压伤:头盔组30/159(18.9%) vs 常规组25/161(15.5%);皮肤压力性损伤:头盔组5/159(3.1%) vs 常规组10/161(6.2%);严重不良事件:头盔组2例 vs 常规组1例。
- 所有预设次要终点两组间均无显著差异。
证据类型、等级与局限
- 证据类型:多中心、实用、随机临床试验(HELMET-COVID)。
- 局限:作者指出解释受效应估计不精确限制,不能排除潜在临床重要获益或危害。
对床旁实践的改变
- 作者认为,在COVID-19所致急性低氧性呼吸衰竭患者中,头盔无创通气与常规呼吸支持相比未显著降低28天死亡率;解读受效应估计不精确限制,不能排除潜在临床重要获益或危害。
指南或共识出处
- HELMET-COVID随机临床试验,ClinicalTrials.gov标识符NCT04477668。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Helmet noninvasive ventilation has been used in patients with COVID-19 with the premise that helmet interface is more effective than mask interface in delivering prolonged treatments with high positive airway pressure, but data about its effectiveness are limited.
OBJECTIVE: To evaluate whether helmet noninvasive ventilation compared with usual respiratory support reduces mortality in patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia.
DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter, pragmatic, randomized clinical trial that was conducted in 8 sites in Saudi Arabia and Kuwait between February 8, 2021, and November 16, 2021. Adult patients with acute hypoxemic respiratory failure (n = 320) due to suspected or confirmed COVID-19 were included. The final follow-up date for the primary outcome was December 14, 2021.
INTERVENTIONS: Patients were randomized to receive helmet noninvasive ventilation (n = 159) or usual respiratory support (n = 161), which included mask noninvasive ventilation, high-flow nasal oxygen, and standard oxygen.
MAIN OUTCOMES AND MEASURES: The primary outcome was 28-day all-cause mortality. There were 12 prespecified secondary outcomes, including endotracheal intubation, barotrauma, skin pressure injury, and serious adverse events.
RESULTS: Among 322 patients who were randomized, 320 were included in the primary analysis, all of whom completed the trial. Median age was 58 years, and 187 were men (58.4%). Within 28 days, 43 of 159 patients (27.0%) died in the helmet noninvasive ventilation group compared with 42 of 161 (26.1%) in the usual respiratory support group (risk difference, 1.0% [95% CI, -8.7% to 10.6%]; relative risk, 1.04 [95% CI, 0.72-1.49]; P = .85). Within 28 days, 75 of 159 patients (47.2%) required endotracheal intubation in the helmet noninvasive ventilation group compared with 81 of 161 (50.3%) in the usual respiratory support group (risk difference, -3.1% [95% CI, -14.1% to 7.8%]; relative risk, 0.94 [95% CI, 0.75-1.17]). There were no significant differences between the 2 groups in any of the prespecified secondary end points. Barotrauma occurred in 30 of 159 patients (18.9%) in the helmet noninvasive ventilation group and 25 of 161 (15.5%) in the usual respiratory support group. Skin pressure injury occurred in 5 of 159 patients (3.1%) in the helmet noninvasive ventilation group and 10 of 161 (6.2%) in the usual respiratory support group. There were 2 serious adverse events in the helmet noninvasive ventilation group and 1 in the usual respiratory support group.
CONCLUSIONS AND RELEVANCE: Results of this study suggest that helmet noninvasive ventilation did not significantly reduce 28-day mortality compared with usual respiratory support among patients with acute hypoxemic respiratory failure due to COVID-19 pneumonia. However, interpretation of the findings is limited by imprecision in the effect estimate, which does not exclude potentially clinically important benefit or harm.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04477668.
参考来源
- Arabi YM, Aldekhyl S, Al Qahtani S, et al. Effect of Helmet Noninvasive Ventilation vs Usual Respiratory Support on Mortality Among Patients With Acute Hypoxemic Respiratory Failure Due to COVID-19: The HELMET-COVID Randomized Clinical Trial. JAMA. 2022. PMID: 36125473. doi:10.1001/jama.2022.15599
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。